KAYRROS
31.3.2020 08:07:10 CEST | Business Wire | Press release
Kayrros SAS, a leading global asset observation platform, is today announcing the latest findings from its technology to track, quantify and attribute global methane emissions. Kayrros uses data from the European Space Agency (ESA) Copernicus program’s Sentinel-5 Precursor satellite and has built a detection and quantification model to trace emissions back to their source. These unique and comprehensive findings show that:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005801/en/
- Methane emissions can now be detected and quantified at an asset level on a global scale , which represents a major step-change in the ability to work towards the reduction of man-made emissions.
- The data shows that there are around 100 high volume-emitting events at any one time around the world. Together, in the course of one year, they are releasing 20 megatons of methane which is equivalent to 1.8 gigatons of CO2 in the first twenty years .1
- Through its proprietary attribution model, Kayrros can identify that around one half of that CO2 equivalent in the first twenty years, or 1 gigaton, are in regions with heavy industry such as oil & gas, coal mining, etc . This is equivalent to the total annual CO2 emissions of Germany and France together.2
Kayrros is a leading Earth observation analytics player able to combine extensive mapping of assets, deep sectoral understanding, and complex machine learning algorithms as well as detection and quantification models in order to identify the missing link between concentrations and emissions.
“What we are announcing today is ground-breaking,” says Antoine Rostand, CEO of Kayrros. “The combination of Sentinel 5-P satellite imagery and Kayrros technology represents a world first in the ability to track and attribute these substantial individual methane leaks. The good news is most of these are man-made and can easily be addressed through action by individual companies, governments and regulators.”
Claus Zehner, Sentinel 5-P Mission manager at ESA, says, “We are pleased to support Kayrros in its use of the Sentinel 5-P data to develop new tools for global methane emissions monitoring. Europe’s investment into satellite technology is ever more crucial if it can support the reduction of global emissions and slow down climate change.”
Kayrros has presented its methodology and approach to the European Commission and its Directorate General for Energy. The upcoming European strategy to reduce methane emissions will include a methodology for methane measurement and quantification that builds on Copernicus and other satellite data for detection and validation. Kayrros remains in dialogue with the European Commission about its work.
Kayrros has also worked with LSCE 3 scientists on Sentinel 5-P imagery to identify and quantify thousands of major methane plumes from various sources around the world. Thomas Lauvaux from the LSCE comments, “To date, only a handful of these large anthropogenic sources have been documented. To expand this, as Kayrros technology does, constitutes a significant step toward mitigating methane emissions around the globe, a significant contributor to climate change, with the support of operators who now have the required information to take immediate action.”
Antoine Rostand emphasizes, “The consequences of these findings are immense, as they enable individual companies in the energy sector to identify and address methane leaks across their networks. Equally, governments and regulators should take note that access to such detailed emissions data will drastically change their ability to hold emitters accountable and potentially reverse the trend of ever-increasing emissions rates.”
This technology is now available to the industry for immediate implementation.
About Kayrros
Kayrros is the leading global asset observation platform worldwide. Harnessing satellite imagery and unconventional data with machine learning, natural language processing and advanced mathematics, Kayrros delivers focused monitoring and measurement of energy and natural resource activity around the world. With access to data on more than 200,000 industry assets, Kayrros customers can observe individual or multiple assets in proprietary or multi-client workflows to analyse industrial and environmental performance for the insight needed to make optimal operational and financial decisions. For more information, please visit www.kayrros.com .
1 |
1 ton of methane is equivalent to 84 tons of CO2 in the first 20 years (Environment Defense Fund ). |
|
2 |
Based on World bank Databank on CO2 emissions for 2014 |
|
3 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005801/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
